Vancomycin has been reported to be from 10 to 82% (mean, 55%) protein bound in pooled serum (1, 3, 4, 9-12, 15, 16, 19) . These reports provide no detailed studies of binding to specific serum proteins, and it is not clear which protein or proteins are the major binding proteins in serum. In fact, information regarding specific binding to albumin is not adequate. The large variations noted (10 to 82%) could be due to a number of factors that include variations between subjects, differences in drug and/or protein concentrations, or differences in assay methods. More important, however, since these studies did not report or control albumin concentrations in the samples, is that these variations could be due to multiple binding proteins in serum. In two studies, it was shown that as albumin concentration in serum increased, the free fraction of vancomycin decreased (4, 15) , but in another study in which albumin concentration was measured, the authors found no correlation between albumin concentration and free drug (1) . Recently, Cantu et al. reported a case of atypical vancomycin pharmacokinetics observed in a patient with immunoglobulin A (IgA) myeloma with serum IgA concentrations varying from 3,600 to 4,610 mg/dl (3) . The patient's serum albumin, total protein, and IgM concentrations were within the normal range, but the IgG concentration was below normal. The free drug in this patient was only 3% of the total, while in control patients free drug concentrations were in the range of 62 to 90%. These results strongly suggest that vancomycin binds to more than one serum protein and that IgA may be an important vancomycin-binding protein in human serum. In view of these, we studied binding characteristics of vancomycin for various serum proteins. Preliminary experiments indicate that vancomycin does not bind to the CENTRIFREE micropartition system filter membrane (Amicon Division, W. R. Grace & Co., Beverly, Mass.) regardless of whether phosphate-buffered saline (PBS) or protein-free normal serum ultrafiltrate is used as the solvent medium. Therefore, we used the ultrafiltration method for separating free from bound drug (17) . Samples were placed in the filter and equilibrated at 37°C for 30 min and then centrifuged at 1,500 x g for 20 min at the same temperature. The free drug concentration in the ultrafiltrate was then quantitated. Vancomycin concentrations in protein solution, ultrafiltrate, and serum were determined by the ion-pair, reversed-phase high-performance liquid chromatography method (8, 13) . The standard curve was linear from 0.1 to 100 ,ug/ml. The limit of detection was 0.1 p,g/ml, at which the within-day coefficient of variation was less than 4% and the overall day-to-day coefficient of variation was less than 7% in either protein solutions, serum (7) , and all initial estimates were determined from Scatchard plots (6, 14) . A model-discriminating F-ratio test and the difference (residual) between measured and computer-fitted concentrations of drug were used to determine the appropriate model (2, 5 yielded the binding site and association constant product (NK) of 527.5 M` ( Fig. 1) .
MATERUILS AND METHODS

Pooled
The percentages of Cbound vancomycin in serum samples with various concentrations of HSA and IgA are shown in Fig. 2 and 3 . No correlation between HSA concentration and percent Cbound in sera was observed when calculations were uncorrected for various concentrations of IgA (Fig. 2a) . A correlation between percent Cbound vancomycin and IgA concentration was observed, one which improved as the Ctotal increased, i.e., r = 0.29, 0.59, and ca. 0.77 at Cttal values of 10, 50, and 80 ,ug/ml, respectively (Fig. 2b) . The correlation improved further after correction for the contri- (Fig. 3) .
The Scatchard plot of data obtained from various serum samples indicates that there are at least two binding sites or binding proteins for vancomycin in serum. A representative plot is shown in Fig. 4 . A model assigning IgA and albumin as the binding proteins resulted in a good fit (Fig. 4 insert) . The IgA binding parameters estimated from the data for the 11 Cbound varied indirectly with C,.,al and the relationship was not linear as shown in Fig. 3 .
In the in vivo study, measured vancomycin free fractions were compared with the predicted values. The predicted and observed values are also in good agreement (Table 2) who reported that at serum IgA concentrations in grams per deciliter, the pharmacokinetics of vancomycin may be adversely affected and, if not considered, may lead to a surprising paradox of very high serum drug levels and a dismal clinical outcome. From our data, we can estimate that, given a normal serum albumin concentration, a serum IgA concentration exceeding 1,000 mg/dl will significantly shorten the time above the MIC of free vancomycin. The calculated serum concentration-time profile for total and free vancomycin for a hypothetical 70-kg man who is given 1,000 mg of vancomycin intravenously and whose serum albumin concentration is 4 g/dl and serum IgA concentration is 200 to 2,000 mg/dl is shown in Fig. 6 . Table 3 gives the calculated free concentration values at various total vancomycin and IgA concentrations in a patient whose serum albumin concentration is 4 g/dl. This figure and this table can be used to estimate the potential effect of high serum IgA on the effective (free) concentration of vancomycin. For patients 
